Skip to main content

For US Healthcare Professionals only

HemAssist logo

Patient support for ALPROLIX®

HemAssist complements the care you provide your patients with support for what’s ahead.


Getting started with ALPROLIX

HemAssist works with you and your patients to get them started on ALPROLIX as efficiently as possible. Our support begins with the enrollment process. As soon as we receive an enrollment form, we can begin a benefits investigation to determine if your patient is eligible for financial assistance.

Our support includes triaging the prescription to the patient's specialty pharmacy and assisting with medication shipments, providing patients with supplemental infusion training when requested, supporting patients with claims and reimbursements, and more.

Alprolix product logo

Our support

Decorative wallet icon

Affording ALPROLIX

No matter your patient's situation, we are committed to helping them access and afford ALPROLIX. The HemAssist team will verify your patient's insurance coverage and determine what financial assistance programs they may be eligible for.

Decorative 1-2-3 steps icon

Starting treatment

The HemAssist team can help your patient get started with ALPROLIX right away. When requested, we can provide supplemental infusion training and offer tips for building a treatment routine.

Decorative conversation bubble icon

Ongoing support

Our team provides support and guidance to your patient throughout the ALPROLIX journey. This includes navigating insurance changes and more. 

Financial assistance

HemAssist works directly with your patients to help identify programs they may be eligible for.

Copay Assistance Program*

HemAssist's Copay Assistance Program may be able to help eligible patients gain access to treatment for as little as $0.

Free Trial Program†

With Free Trial, patients can get their first 30-day supply of treatment generally within 24 to 48 hours with a valid prescription.  While you and your patient are deciding what treatment is right for them, a dedicated Sanofi Case Manager will review their health insurance information and coverage for ALPROLIX. Once the enrollment is complete, a dedicated Sanofi Case Manager will contact your patient within 24 hours with next steps.

Patient Assistance Program†

HemAssist's Patient Assistance Program may be available to help eligible ALPROLIX patients who are uninsured, underinsured, or experiencing a temporary loss of insurance coverage.

*Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their ALPROLIX prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their ALPROLIX prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

† Free Trial valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free Trial not valid in Vermont. Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Meet your team

HemAssist works directly with your patients to help identify programs they may be eligible for.

HemAssist team member sitting at a desk with a headset

Clinical Educator (CE)

CEs can answer questions from you or your patients about ALPROLIX and can provide patients with helpful support including treatment tips and supplemental administration training.

Portrayal of a smiling man sitting at a desk wearing a headset

Case Managers

Case Managers provide you with personalized insurance investigations and answer questions about financial assistance options for eligible patients. They can help coordinate treatment shipments and assist with reimbursements.

Portrayal of an woman in an office speaking into a headset

Field Reimbursement Managers (FRM)

Our FRMs can navigate insurance coverage and provide reimbursement education and solutions on behalf of patients.

Ready to enroll a patient in HemAssist?

It takes just a few steps. Enroll online or download and fax an enrollment form. 

INDICATION

ALPROLIX is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

LIMITATION OF USE

ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS

  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.

INDICATION

IMPORTANT SAFETY INFORMATION

HemAssist Sanofi Support Here for your patients throughout their treatment journey. Call 1-833-723-5463 Monday – Friday 8 AM to 7 PM ET Fax 1-855-398-7634 © 2025 Sanofi. All rights reserved. ALPROLIX, HemAssist, and Sanofi are trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2505183-v1.0-08/2025